S.NO	AM: M. PHARMACY (P COURSE/CODE	GENDER	ENVIRONMENT AND SUSTAINABILITY	HUMAN VALUES	PROFESSIONAL ETHICS
1.	DRUG DELIVERY SYSTEMS (MPH 102T)			Vaccine delivery systems: Vaccines, uptake of antigens, single Shot vaccines, mucosal and transdermal delivery of vaccines.	
2.	MODERN PHARMACEUTICS (MPH103T)				Validation: Introduction to Pharmaceutical Validation, Scope & merits of Validation Validation and calibration of Master plan, ICH & WHO guidelines for calibration and validation of equipments, Validation of specific dosage form, Types of validation. Government regulation, Manufacturing Process Model, URS, DQ, IQ, OQ & P.Q. of facilities. cGMP & Industrial Management: Objectives and policies of current good manufacturing practices, layout of buildings, services,





			equipments and their
- 1			maintenance Production
			management: Production
			organization, , materials
			management, handling and
			transportation, inventory
			management and control,
			production and planning
			control, Sales forecasting,
	<u>*</u>		budget and Cost control,
			industrial and personal
			relationship. Concept of Total
			Quality Management.
			Compression and
			compaction: Physics of
			tablet compression,
			compression, consolidation,
			effect of friction, distribution
			of Forces, compaction
			profiles. Solubility. Study of
			consolidation parameters;
	8		Diffusion parameters,
			Dissolution parameters and
			Pharmacokinetic parameters,
			Haeckel plots, Similarity
			factors – f2 and f1, Higuchi
		194	and Peppas plot, Linearity
		DITTATRACE	Concept of significance,
		15	Standard deviation, Chi
		STATE TO THE STATE OF THE STATE	XX
		ALEN YOU	PHINCIPAL College
			Aditya Pharmacy College
			Aditya Pharmacy College SURAMPALEM-533 437

			square test, students T-test, ANOVA test.
3.	REGULATORY AFFAIRS (MPH 104T)	Clinical trials: Developing clinical trial protocols. Institutional review board/ independent ethics committee Formulation and working procedures informed Consent process and procedures and HIPPA-new requirement to clinical study process, pharmacovigilance safety monitoring in clinical trials.	Documentation in Pharmaceutical industry: Master formula record, DMF (Drug Master File), distribution records. Generic drugs product development Introduction, Hatch-Waxman act and amendments, CFR (CODE OF FEDERAL REGULATION), drug product performance, in- vitro, ANDA regulatory approval process, NDA approval process, BE and drug product assessment, in – vivo, scale up process approval changes, post marketing surveillance, outsourcing BA and BE to CRO. Regulatory requirement for product approval: API, biologics, novel, therapies obtaining NDA, ANDA for generic drugs ways and means of US registration for
		MPALEN	Adity Phannacy Conege SURAMPALEM 533 937

foreign drugs. CMC, post approval regulatory affairs. Regulation for combination products and medical devices. CTD and ECTD format, industry and FDA liaison. ICH - Guidelines of ICH-Q, S E, M. Regulatory Requirements of EU, MHRA, TGA and ROW countries. Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS (MPH 202T) PHARMACOKINETICS (MPH 202T) ADVANCED BIOPHARMACOKINETICS (MPH 202T) PHARMACOKINETICS (MPH 202T)					foreign drugg CMC nost
Regulation for combination products and medical devices. CTD and ECTD format, industry and FDA liaison. ICH - Guidelines of ICH-Q, S E, M. Regulatory Requirements of EU, MHRA, TGA and ROW countries. Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & Drug Product Performance, In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability, Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					
products and medical devices. CTD and ECTD format, industry and FDA liaison. ICH - Guidelines of ICH-Q, S E, M. Regulatory Requirements of EU, MHRA, TGA and ROW countries. Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS (MPH 202T) Drug Product Performance, In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					**
CTD and ECTD format, industry and FDA liaison. ICH - Guidelines of ICH-Q, S E, M. Regulatory Requirements of EU, MHRA, TGA and ROW countries. Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS (MPH 202T) PHARMACOKINETICS (MPH 202T) CTD and ECTD format, industry and FOA liaison. ICH - Guidelines of ICH-Q, S E, M. Regulatory Requirements of EU, MHRA, TGA and ROW countries. Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). Drug Product Performance, In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					The state of the s
industry and FDA liaison. ICH - Guidelines of ICH-Q, S E, M. Regulatory Requirements of EU, MHRA, TGA and ROW countries. Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS (MPH 202T) PHARMACOKINETICS (MPH 202T) industry and FDA liaison. ICH - Guidelines of ICH-Q, S E, M. Regulatory Requirements of EU, MHRA, TGA and ROW countries. Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). Drug Product Performance, In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					[[전 스트 (12) 전에 있는데 어린 12 시간에 다 이번에 있는데 되었습니다. 그런데 그 이번에 그 그 그 그 그 그 그 그 그 그 그 그 그 그 그 그 그 그 그
ICH - Guidelines of ICH-Q, S E, M. Regulatory Requirements of EU, MHRA, TGA and ROW countries. Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). Drug Product Performance, In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of		1			
E, M. Regulatory Requirements of EU, MHRA, TGA and ROW countries. Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS (MPH 202T) BIOPHARMACOKINETICS (MPH 202T)					industry and FDA liaison.
Requirements of EU, MHRA, TGA and ROW countries. Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & Drug Product Performance, In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					ICH - Guidelines of ICH-Q, S
TGA and ROW countries. Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). Drug Product Performance, In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					E, M. Regulatory
Non clinical drug development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). Drug Product Performance, In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					Requirements of EU, MHRA,
development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					TGA and ROW countries.
development: Global submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					Non clinical drug
submission of IND, NDA, ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS (MPH 202T) Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					_
ANDA. Investigation of medicinal products dossier, dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & In Vivo: Bioavailability and Bioequivalence: drug product performance, uprpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of		Sec			submission of IND, NDA,
medicinal products dossier, dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS (MPH 202T) MPH 202T) medicinal products dossier, dossier (IMPD) and investigator brochure (IB). Drug Product Performance, In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					1
dossier (IMPD) and investigator brochure (IB). 4. ADVANCED BIOPHARMACEUTICS & In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					_
4. ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS (MPH 202T) Markin investigator brochure (IB). Drug Product Performance, In Vivo: Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					
4. ADVANCED BIOPHARMACEUTICS & BIOPHARMACOKINETICS (MPH 202T) MPH 202T) ADVANCED BIOPHARMACOKINETICS (MPH 202T) Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					
BIOPHARMACEUTICS & PHARMACOKINETICS (MPH 202T) Bioavailability and Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of	1	ADVANCED			
Bioequivalence: drug product performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of	4.				
PHARMACOKINETICS (MPH 202T) performance, purpose of Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					-
(MPH 202T) Bioavailability studies, relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of		100.000 Lipino			
relative and absolute availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of					1.
availability. Methods for assessing bioavailability, bioequivalence studies, design and evaluation of		(MPH 2021)			
assessing bioavailability, bioequivalence studies, design and evaluation of					
bioequivalence studies, design and evaluation of					-
design and evaluation of					
2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5				- arrivers	
bloedulvalence studies, study				S. SHAKMACA	
(9) (5)				187 18	blocquivalence studies, study

Aditya Pharmacy College SURAMPALEM.533 437

				designs, crossover study
n .			I .	degions evaluation of the
				designs, evaluation of the data, bioequivalence
				example, Study submission
				and drug review process.
				Biopharmaceutics
				Classification system,
				methods. Permeability: In-
				vitro, in-situ and In-vivo
	99			methods. Generic biologics
				(biosimilar drug products),
				clinical significance of
				bioequivalence studies,
				special concerns in
				bioavailability and
				bioequivalence studies,
				generic substitution.
				1. a. Computers in
DRUG DEVELOPMENT				Pharmaceutical Research
(MPH 203T)				and Development: A
				General Overview: History of
				Computers in Pharmaceutical
				Research and Development.
				Statistical modeling in
				Pharmaceutical research and
				development: Descriptive
			TIA PHLICE	versus Mechanistic
			3 5	Modeling, Statistical
			\$ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	PRINCIPAL COLLEG
			340 55	Aditya Pharmacy Colleg SURAMPALEM-533 437
	COMPUTER AIDED DRUG DEVELOPMENT (MPH 203T)	DRUG DEVELOPMENT	DRUG DEVELOPMENT	DRUG DEVELOPMENT

			Devemptors Estimation
			Parameters, Estimation,
			Confidence Regions,
-			Nonlinearity at the Optimum,
			Sensitivity Analysis, Optimal
			Design, Population Modeling
			b. Quality-by-Design In
			Pharmaceutical
			Development:
			Introduction, ICH Q8
			guideline, Regulatory and
			industry views on QbD,
			Scientifically based QbD -
			examples of application.
			2. Computational Modeling
			Of Drug Disposition:
			Introduction, Modeling
			Techniques: Drug
			Absorption, Solubility,
			Intestinal Permeation, Drug
			Distribution ,Drug Excretion,
			Active Transport; P-gp,
			BCRP, Nucleoside
	*		Transporters, hPEPT1,
			ASBT, OCT, OATP, BBB-
			Choline Transporter.
			3. Computer-aided
		Call to The	formulation development:
		A Principal	1 2 1
		100	Concept of optimization,
		E S	Optimization parameters,
		THOATEN TO	2
			PRINCIPAL Aditya Pharmacy Colleg SURAMPALEM-533 437
			Adiya Phamacy
			SURVIVI

Factorial design, Optimization technology & Screening design. Computers in Pharmaceutical Formulation: Development of pharmaceutical emulsions, micro emulsion drug carriers Legal Protection of Innovative Uses of Computers in R&D, The Ethics of Computing in Pharmaceutical Research, Computers in Market analysis. 4 a. Computer-aided biopharmaceutical characterization: Gastrointestinal absorption simulation. Introduction, Theoretical background, Model construction, Parameter sensitivity analysis, Virtual trial, Fed vs. fasted state, In vitro dissolution and in-vitro, invivo correlation, Biowaiver considerations. b. Computer Simulations in

> Aditya Pharmacy College SURAMPAIFM 533 437

	Pharmacokinetics and Pharmacodynamics:
	Introduction, Computer
	Simulation: Whole Organism,
	Isolated Tissues, Organs,
	Cell, Proteins and Genes.
	c. Computers in Clinical
	Development: Clinical Data
	Collection and Management,
	Regulation of Computer
	Systems.
	5. Artificial Intelligence
	(AI), Robotics and
	Computational fluid
	dynamics: General overview,
	Pharmaceutical Automation,
	Pharmaceutical applications,
	Advantages and
	Disadvantages. Current
	Challenges and Future
	Directions.



